Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study
Emanuel Della‐Torre, Marco Lanzillotta, Corrado Campochiaro, Giulia Di-Colo, Gaia Mancuso, Gabriele Capurso, Massimo Falconi, Lorenzo Dagna
Topics & Concepts
MedicineRituximabBiosimilarIgG4-related diseaseInternal medicineGastroenterologyCohortDiseaseLymphomaIgG4-Related and Inflammatory DiseasesImmunodeficiency and Autoimmune DisordersMonoclonal and Polyclonal Antibodies Research